AHPRA Evidence Standards Update 2026 | New Requirements

What Changed in AHPRA's Evidence Requirements for Advertising?

AHPRA has replaced its 'Acceptable evidence framework' with new guidance titled 'Acceptable evidence in health advertising', alongside three additional resources: an advertising compliance and enforcement strategy document, a consolidated case law database, and updated advertising complaints guidance. These changes represent the most significant update to AHPRA's evidence substantiation requirements since the March 2020 Advertising Guidelines.

The previous 'Acceptable evidence framework' provided foundational guidance on what types of evidence could support advertising claims made by health practitioners. The replacement document, 'Acceptable evidence in health advertising', maintains the core principle that all claims must be substantiated but provides updated standards reflecting current regulatory expectations and recent enforcement outcomes.

In plain English: If you make a claim about a treatment, service, or product in any advertising — your website, social media, brochures, emails — you must hold evidence that supports that claim before you publish it. The new guidance clarifies exactly what AHPRA considers acceptable evidence.

Alongside the evidence update, AHPRA has published a formal 'Advertising compliance and enforcement strategy' document. This is the first time AHPRA has publicly detailed its systematic approach to assessing advertising complaints, conducting investigations, and determining whether to pursue prosecution. The strategy document outlines risk-based assessment criteria, investigation procedures, and the factors AHPRA considers when deciding between education, compliance action, or prosecution.

The new 'Advertising cases heard by courts and tribunals' resource consolidates published decisions where advertising breaches have been prosecuted. This case law database provides practitioners with concrete examples of what has been found non-compliant in legal proceedings, including specific language, claims, and advertising formats that have resulted in penalties.

Why Do Updated Evidence Standards Matter for Practitioners?

The updated evidence guidance directly affects your legal exposure under Section 133 of the Health Practitioner Regulation National Law. Claims that cannot be substantiated with acceptable evidence constitute advertising offences, carrying penalties of up to $60,000 for individual practitioners and up to $120,000 for bodies corporate per offence. The new enforcement strategy document reveals exactly how AHPRA assesses whether your evidence is sufficient.

Many practitioners operate under the misconception that "evidence" means simply having treated patients with good outcomes, or having attended a training course on a particular technique. The updated guidance makes clear that acceptable evidence must be objective, verifiable, and proportionate to the claim being made.

For example, if you claim a treatment "reduces pain by 70%", you must hold clinical evidence demonstrating that specific outcome — patient testimonials, your clinical experience, or training certificates do not constitute acceptable evidence for a quantified therapeutic claim. If you claim a product is "clinically proven", you must hold published peer-reviewed research supporting that claim for the specific product and indication you're advertising.

In plain English: Your subjective experience and patient satisfaction are not acceptable evidence for objective therapeutic claims. You need clinical studies, peer-reviewed research, or regulatory approvals that specifically support each claim you make.

The new enforcement strategy document is particularly significant because it reveals AHPRA's risk-based assessment model. High-risk advertising — including cosmetic procedure promotion, prescription medicine references, and claims targeting vulnerable populations — receives heightened scrutiny and is more likely to result in prosecution rather than educational warnings. Understanding this risk framework allows practitioners to identify which advertising materials require immediate review and which claims carry the highest regulatory exposure.

The consolidated case law database provides concrete examples of where practitioners have failed to meet evidence requirements. Recent cases have resulted in penalties for claims including "proven results", "clinically effective", percentage-based outcome claims, and comparative superiority statements — all made without holding appropriate substantiating evidence at the time of publication.

What Evidence Is Acceptable Under the Updated Standards?

Acceptable evidence must be objective, verifiable, current, and proportionate to the claim being made. The updated guidance emphasises that evidence must exist before publication, must be specific to the product or service being advertised, and must support the precise claim being made — not a related or generalised claim. Practitioners bear the burden of proof to demonstrate they held appropriate evidence at the time of publication.

The updated 'Acceptable evidence in health advertising' guidance maintains the hierarchy of evidence quality established in the previous framework but provides enhanced clarity on what constitutes sufficient substantiation for different claim types:

For therapeutic or outcome claims (e.g. "reduces symptoms", "improves function", "clinically proven"), acceptable evidence includes: systematic reviews and meta-analyses of randomised controlled trials; peer-reviewed published research specific to the treatment and indication; Therapeutic Goods Administration (TGA) approvals and registered indications for therapeutic goods; clinical practice guidelines from recognised professional bodies.

For factual claims about qualifications or credentials (e.g. "AHPRA-registered specialist", "Fellow of [College]"), acceptable evidence includes: AHPRA specialist registration records; professional college fellowship certificates; university degree certificates and transcripts; verifiable professional memberships.

For claims about practice characteristics (e.g. "20 years' experience", "state-of-the-art equipment"), acceptable evidence includes: verifiable employment records and AHPRA registration history; equipment purchase records and technical specifications; practice accreditation certificates.

In plain English: The bigger the claim, the stronger the evidence required. If you're claiming a treatment works, you need published research. If you're claiming you're qualified, you need registration or certification records. If you're claiming your equipment is advanced, you need technical specifications proving that.

The updated guidance explicitly states that the following do NOT constitute acceptable evidence for therapeutic claims: patient testimonials or reviews; before-and-after images alone; practitioner clinical experience or anecdotal observations; attendance at training courses or workshops; manufacturer marketing materials or claims; social media posts or influencer endorsements.

This is particularly important for practitioners who have relied on training certificates or manufacturer-provided materials to support advertising claims. A certificate confirming you completed training in a technique does not constitute evidence that the technique achieves specific therapeutic outcomes.

What Do Practitioners Need to Do Immediately?

All AHPRA-registered practitioners must conduct an immediate audit of current advertising materials against the updated evidence standards, identify claims that cannot be substantiated with acceptable evidence, and either remove those claims or obtain appropriate evidence before continuing to advertise. The burden of proof rests with the practitioner to demonstrate they held acceptable evidence at the time of publication.

For practitioners advertising cosmetic procedures, this evidence review is particularly critical. The September 2025 updates to AHPRA's cosmetic surgery advertising guidelines already imposed enhanced requirements for higher-risk procedures. The updated evidence standards apply on top of those cosmetic-specific requirements — you must comply with both frameworks simultaneously.

If you make claims about success rates, patient satisfaction, or treatment outcomes, you should review our detailed analysis in "Your 'Success Rate' Claims Could Be Non-Compliant", which examines evidence requirements for quantified outcome claims.

For practitioners who have relied on patient testimonials or reviews to support service claims, the prohibition remains absolute under Section 133. Our briefing "Your Google Reviews May Trigger AHPRA Penalties" explains why patient reviews cannot substitute for objective evidence and how to manage testimonial content on platforms you control.

How Does AHPRA's Enforcement Strategy Affect Your Compliance Risk?

The newly published 'Advertising compliance and enforcement strategy' reveals that AHPRA uses a risk-based assessment model to determine whether advertising complaints result in education, compliance action, or prosecution. High-risk factors include advertising higher-risk cosmetic procedures, targeting vulnerable populations, making unsubstantiated therapeutic claims, and repeat non-compliance. Understanding this risk framework allows practitioners to prioritise compliance efforts on the highest-exposure content.

The enforcement strategy document outlines a three-tier response framework. Low-risk, first-time technical breaches may result in educational contact and voluntary compliance. Medium-risk breaches typically trigger formal compliance notices requiring corrective action within specified timeframes. High-risk breaches — particularly those involving patient safety concerns, vulnerable populations, or deliberate non-compliance — proceed directly to investigation and potential prosecution.

In plain English: AHPRA doesn't prosecute every complaint. They assess risk and compliance history. But if you're advertising cosmetic procedures, making bold therapeutic claims, or you've been warned before, you're much more likely to face formal enforcement action rather than just a warning.

The strategy document identifies specific high-risk advertising categories that receive enhanced scrutiny: prescription medicine references or Schedule 4 substance promotion; higher-risk cosmetic procedures as defined in the September 2025 updates; advertising targeting individuals under 18; claims about treating serious conditions without appropriate evidence; comparative superiority claims without objective substantiation; financial inducements or promotional offers without clear terms.

Practitioners with previous advertising complaints or compliance notices are flagged for escalated enforcement responses. The strategy explicitly states that repeat non-compliance demonstrates a failure to meet professional obligations and weighs heavily in prosecution decisions. This means your compliance history matters — a first technical breach might be managed educationally, but subsequent breaches are likely to result in penalties.

The case law database published alongside the strategy document shows that recent prosecutions have resulted in penalties ranging from $15,000 to $60,000 for individual practitioners, with higher penalties for bodies corporate and repeat offenders. Courts have imposed penalties at the upper end of the range for advertising involving cosmetic procedures, unsubstantiated therapeutic claims, and deliberate non-compliance after prior warnings.

For practitioners in cosmetic practice, the combination of the September 2025 cosmetic procedure updates and the new enforcement strategy creates significantly elevated compliance risk. Our comprehensive analysis "AHPRA Updates Cosmetic Surgery Advertising Guidelines" examines the specific requirements for higher-risk procedures and how they interact with evidence standards.

Understanding the enforcement strategy allows you to conduct risk-based prioritisation of compliance work. Advertising for higher-risk cosmetic procedures, prescription injectable references, and therapeutic outcome claims should receive immediate attention and the most conservative compliance approach. Factual service descriptions, practitioner qualifications (where verifiable), and educational content about conditions carry lower enforcement risk.

What Does This Mean for Ongoing Advertising Compliance?

The updated evidence standards and published enforcement strategy signal a maturation of AHPRA's advertising regulation from principle-based guidance to detailed, enforceable standards with transparent prosecution criteria. Practitioners can no longer rely on ambiguity or inconsistent enforcement — the regulatory expectations are now clearly documented, and the enforcement pathway is formalised. Ongoing compliance requires systematic evidence management, not reactive complaint response.

The shift from 'Acceptable evidence framework' to 'Acceptable evidence in health advertising' reflects AHPRA's evolution from educating practitioners about new requirements (following the March 2020 Guidelines) to enforcing established standards with clear precedent. The publication of the enforcement strategy and case law database indicates AHPRA considers the education phase complete and is moving to consistent, risk-based enforcement.

For practitioners, this means compliance can no longer be addressed reactively when complaints arise. The enforcement strategy makes clear that AHPRA expects practitioners to have reviewed and understood the requirements, to have audited their advertising against those requirements, and to hold documented evidence for all claims before publication. "I didn't know" or "I didn't think that applied to me" are not defences — the guidance is publicly available and applies to all AHPRA registrants.

In plain English: AHPRA has published the rules, published the enforcement process, and published examples of what breaks the rules. If you get caught non-compliant now, you can't claim you didn't know. The expectation is that you've done the work to understand and comply.

The practical implication is that advertising compliance must become a documented, systematic process within your practice. Before publishing any advertising content — website updates, social media posts, promotional emails, new brochures — you should complete an evidence checklist confirming that every claim is supported by documented, acceptable evidence. This evidence file should be maintained and updated as new research emerges or regulatory approvals change.

For multi-practitioner practices and corporate healthcare providers, the updated standards require governance frameworks ensuring all practitioners and marketing staff understand evidence requirements. Bodies corporate face penalties up to $120,000 per offence, and the enforcement strategy indicates that corporate healthcare advertisers receive enhanced scrutiny due to their larger public reach and commercial sophistication.

Practitioners using AI tools or automated content generation for advertising materials face particular challenges. AI-generated content frequently makes unsubstantiated claims, uses prohibited testimonial-style language, or references outcomes without supporting evidence. Our analysis "The Compliance Scalpel vs. Generic AI Tools" examines why general-purpose AI tools cannot ensure AHPRA compliance and the specific risks of AI-generated advertising content.

The updated guidance reinforces that practitioners remain legally responsible for all advertising content published under their name or for their practice, regardless of who created it. If a marketing agency, website developer, or AI tool generates non-compliant content, you bear the regulatory liability. This makes systematic review against documented evidence standards essential before publication.